United Capital Financial Advisors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

United Capital Financial Advisors’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-5,671	Closed	-$473K	–	1253
2021 Q3	$473K	Buy	5,671 +141	+3%	+$11.7K	﹤0.01%	876
2021 Q2	$525K	Hold	5,530	–	–	﹤0.01%	849
2021 Q1	$920K	Buy	5,530 +1,300	+31%	+$172K	0.01%	694
2020 Q4	$415K	Hold	4,230	–	–	﹤0.01%	898
2020 Q3	$144K	Hold	4,230	–	–	﹤0.01%	1095
2020 Q2	$240K	Hold	4,230	–	–	﹤0.01%	1050
2020 Q1	$248K	Buy	4,230 +355	+9%	+$26.5K	﹤0.01%	1017
2019 Q4	$306K	Buy	3,875 +57	+1%	+$5.9K	﹤0.01%	1131
2019 Q3	$382K	Buy	+3,818	New	+$391K	﹤0.01%	1025

Other funds holding ONCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

United Capital Financial Advisors's ONCT Position: Q4 2021 in Review

United Capital Financial Advisors sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2021, closing a stake of 5,671 shares — an estimated $473K sold.

United Capital Financial Advisors first reported a position in ONCT in Q3 2019 and held it in 9 quarters. The position peaked at $920K in Q1 2021. 82 funds tracked by Wall St. Rank hold ONCT as of Q4 2021.

United Capital Financial Advisors reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
United Capital Financial Advisors sold 5,671 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $473K.
United Capital Financial Advisors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2019 and held it in 9 quarters.
United Capital Financial Advisors's Oncternal Therapeutics, Inc. Common Stock position peaked at $920K in Q1 2021.
82 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2021.

Based on United Capital Financial Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.